Survey: Workers reluctant to call in sick because of too much work and staffing issues
10 Feb, 2021 05:00 PM
4 minutes to read
A new survey has found workers are hesitant to call in sick because of staffing and leave issues. Photo / Getty
A new survey has found workers are hesitant to call in sick because of staffing and leave issues. Photo / Getty
New Zealanders are reluctant to call in sick despite feeling unwell because there was no one to cover them or there was too much work to do, a new survey has found.
The report for recruitment agency Onestaff revealed the top five reasons people were hesitant to take sick leave - with 53 per cent blaming being short-staffed as the number one reason.
Message :
Required fields
HOUSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) Crown Castle International Corp. (NYSE: CCI) ( Crown Castle ) announced today that it has priced its previously announced public offering of 1.050% Senior Notes due 2026, 2.100% Senior Notes due 2031, and 2.900% Senior Notes due 2041, in aggregate principal amounts of $1.0 billion, $1.0 billion and $1.25 billion, respectively. The Senior Notes due 2026 will have an interest rate of 1.050% per annum and will be issued at a price equal to 99.686% of their face value to yield 1.110%. The Senior Notes due 2031 will have an interest rate of 2.100% per annum and will be issued at a price equal to 99.546% of their face value to yield 2.150%. The Senior Notes due 2041 will have an interest rate of 2.900% per annum and will be issued at a price equal to 99.558% of their face value to yield 2.929%.
MedCity News
Nautilus Bio lines up SPAC merger and $350M in funding for proteomics R&D
Nautilus, among the biotechs developing protein analysis tools for drug discovery and diagnostics, already has a partnership with Genentech. As it prepares to go public, Nautilus aims to do for proteomics what Illumina did for genomics.
Shares1
Nautilus Biotechnology is joining the public markets through a merger that provides it with $350 million to ramp up work developing its protein analysis technology for drug discovery and diagnostic applications.
Seattle-based Nautilus is combining with Arya III, a special purpose acquisition company (SPAC), which is a publicly traded entity formed as a vehicle for other companies to go public. The combined company, which will be run by Nautilus’s management, will have a valuation of about $900 million. When the deal closes, Nautilus expects that its shares will trade on the Nasdaq under the stock symbol “NAUT.”
Oscar Health filed preliminary paperwork for an IPO on Friday. The health insurance startup is betting that its technology can give it an edge as it fights for market share with bigger competitors.